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Frequent discrepancies between preclinical and clin-
ical results of anticancer agents demand a reliable
translational platform that can precisely recapitulate
the biology of human cancers. Another critical unmet
need is the ability to predict therapeutic responses
for individual patients. Toward this goal, we have
established a library of orthotopic glioblastoma
(GBM) xenograft models using surgical samples of
GBM patients. These patient-specific GBM xeno-
graft tumors recapitulate histopathological proper-
ties andmaintain genomic characteristics of parental
GBMs in situ. Furthermore, in vivo irradiation,
chemotherapy, and targeted therapy of these xeno-
graft tumors mimic the treatment response of
parental GBMs. We also found that establishment
of orthotopic xenograft models portends poor prog-
nosis of GBM patients and identified the gene signa-
tures and pathways signatures associated with
the clinical aggressiveness of GBMs. Together, the
patient-specific orthotopic GBM xenograft library
represent the preclinically and clinically valuable
‘‘patient tumor’s phenocopy’’ that represents molec-
ular and functional heterogeneity of GBMs.INTRODUCTION
Glioblastoma (GBM) is the most common and lethal primary
brain tumor. Aggressive standard-of-care therapy including260 Cell Reports 3, 260–273, January 31, 2013 ª2013 The Authorsconcurrent chemoradiation treatment based on the oral methyl-
ator temozolomide (TMZ) and more recent molecular-targeted
therapeutics provide only palliation, unable to change the near
uniform lethality of this disease (Adamson et al., 2009; Chi and
Wen, 2007; Furnari et al., 2007). However, differential responses
of GBM patients to the TMZ-based chemotherapy has been
recognized and it is now believed that therapeutic benefit by
TMZ is much greater in a cohort of GBMs with low expression
of O6-methylguanine-DNA methyl transferase (MGMT) (Hegi
et al., 2005; Stupp et al., 2005). This prototypic example high-
lights the importance of molecular and genetic GBM heteroge-
neity in the development of novel therapeutics and companion
diagnostics (Nicholas et al., 2011).
Traditionally, preclinical cancer biology has largely relied on
the use of human cancer cell lines in vitro and the xenograft
tumor models derived from these cell lines. However, the
process of establishing conventional GBM cell lines results in
irreversible loss of important biological properties and, as a
result, the xenograft tumor models do not maintain genomic
and phenotypic characteristics present in the original tumor
(Martens et al., 2008; Sausville and Burger, 2006; Taillandier
et al., 2003). More importantly, loss of specific properties of indi-
vidual tumors induces the failure to represent theGBMheteroge-
neity (Bonavia et al., 2011; Lee et al., 2006; Verhaak et al., 2010).
Therefore, it is questionable whether those preclinical platforms
can serve as a reliable ‘‘filter’’ to select the lead candidate
compounds or ‘‘tester’’ to determine the therapeutic efficacy of
drugs.
It has been postulated that in vitro and in vivo preclinical
models using primarily cultured GBM cells recapitulate the
biology of the disease more precisely (Lee et al., 2006; Xie
et al., 2008). However, it is still controversial whether those trans-
lational models would be functionally better, because thorough
preclinical and clinical validation of the platform using compa-
rable GBM patient population and corresponding animal models
has not been addressed yet. Here, we report the establish-
ment of the matched in vitro and in vivo GBM model systems
that are derived from patient specimens. We provide evidence
that this preclinical model recapitulate the biology of human
GBM in situ, and precisely verified their preclinical and clinical
implications.
RESULTS
In Vitro Cultures and Orthotopic Xenograft Tumor
Models
Seventy-one surgical specimens (Table 1; Figure S1) were
collected from 59 GBM patients (from 11 patients, both primary
and recurrent tumor specimens were acquired; from one patient,
two recurrent specimenswith no primary sample were acquired).
We dissociated GBM cells from each specimen and stereotacti-
cally injected into thebrainsof immune-compromisedNOD/SCID
Il2rg/ (NOG) mice (Ito et al., 2002) within 12 hr after surgery. In
parallel, in vitro growth kinetics of the freshly isolated GBM cells
were determined by culturing them in serum-free media in the
presence of EGF and bFGF (Joo et al., 2008). Because clono-
genic growth as neurospheres is an in vitro indicator of self-
renewal in GBM stem cells, we used sphere formation (diameter
R50mm)as the readout for in vitro growthofGBMs. In vivo tumor-
igenicity was defined as the formation of tumor within 12 months
after tumor cell injection. Due to technical issues including the
limited number of cells available, we could not test one sample
for in vivo tumorigenic potential and 21 samples for in vitro sphere
formation capacity (Table 1; Figure S1).
With this paralleled in vivo xenograft tumors and in vitro short-
term cultures, we determined a potential correlation between the
two. In vivo xenograft tumor formation was histopathologically
confirmed in 53 cases from 70 samples (75.7%) (Table 1; Figures
1A and S1A). Robust in vitro sphere formation and sustained
growth was confirmed in 34 cases from 50 samples (68.0%)
(Table 1; Figures 1A and S1B). There appeared to be a positive
correlation; however, it was not statistically significant (Fisher’s
exact test, p = 0.09; Figure 1B).
In Vivo Tumorigenicity and Clinical Aggressiveness of
Parental Tumors
Both in vitro primary cultures and orthotopic xenograft tumor
models are the crucial parts of preclinical evaluation platform
for new anticancer therapeutics. We reasoned that the readouts
of an adequate platform should be able to represent pathoclini-
cal parameters of patients. With this notion, we correlated the
in vitro growth or xenograft tumor formation with the clinical
information of the GBM patients. Progression free survival
(PFS) and overall survival (OS) of the patients were utilized as
indicators of GBM aggressiveness. Clinical data of primary
GBMs (n = 58) was utilized for survival analysis, from which
PC-NS08-532 and IRCR-GBM10-022 were excluded due to
mortality derived from the pulmonary embolism and follow-up
loss, respectively (Table 1; Figures S1A and S1B).
In a subset of GBMs with robust in vitro sphere formation (Fig-
ure S1B, n = 29), PFS and OS were 40.0 (28.1–51.9) weeks andC73.0 (53.4–92.6) weeks (median [95% confidence interval]),
respectively. The PFS and OS were not statistically different
from those of the other group (Figure S1B, n = 15, PFS = 44.0
[33.3–54.7] weeks [p = 0.815], OS = 82.0 [58.0–106.0] weeks
[p = 0.380]), suggesting that in vitro sphere formation cannot
portend the patient survival (Figure S2A). A previous study has
reported that adherent cultures using laminin as a cohesive
substrate could improve the survival and growth of GBM
cells compared to the sphere culture (Pollard et al., 2009). We
cultured 17 different GBM cells using both conditions. How-
ever, overall growth patterns of the two primary cultures were
indistinguishable (Figure S2C). Therefore, it is unlikely that the
apparent lack of correlation between in vitro growth and the
patient survival is due to the use of inadequate in vitro culture
condition.
In contrast, in vivo tumor formation capacities of dissociated
GBM cells appeared to correlate with worse clinical outcome
(GBMs with tumor formation capacity: n = 40, PFS = 41.0
[32.5–49.5] weeks, OS = 71.0 [54.7–87.3] weeks versus GBMs
without the capacity: n = 16, PFS = 53.0 [40.4–65.6] weeks
[p = 0.075], OS = 82.0 [76.2–87.8] weeks [p = 0.303]), although
the trend fell short of statistical significance (Figures 1C and
S1A). There was no significant correlation between the in vivo
tumorigenic potential and other clinical factors such as sex,
age, location of lesion, and initial KPS (data not shown; Table 1).
Next, we examined the growth pattern of the patient-derived
tumors. Many of xenograft GBM tumors revealed a highly inva-
sive and infiltrative tumor growth pattern, whereas the other
xenograft tumors revealed a clear demarcation (Figure 2A). Inva-
sive GBM growth is a major culprit for lethality because it makes
complete surgical resection of the tumor impossible. Consid-
ering the profound clinical implication of the invasiveness, we
classified the primary GBM patients into two groups: (1) GBMs
that generated invasive tumor in mouse brains (n = 27), and (2)
GBMs that failed to make tumor or made well-demarcated
tumors (n = 29; Table 1; Figure S1A). When PFS and OS of these
two groups were compared (Figure S2B), the former group
showed a significantly shorter OS (64.0 [59.3–68.7] weeks)
than the latter group (99.0 [38.7–159.3] weeks, p < 0.001). PFS
was also significantly different between these groups (39.0
[34.0–44.0] weeks versus 54.0 [36.6–71.4] weeks, p = 0.013).
Together, these data suggest that an invasive tumor growth
pattern of orthotopic xenograft tumors is a prognostic factor to
predict the clinical outcomes of parental GBMs.
Morphologic and Pathologic Similarity
The utility of orthotopic GBM xenografts as a model system of
human GBM in situ would be greatly increased if xenograft
tumors precisely reflect morphologic and pathologic character-
istics of their parental tumors. To test, we compared three key
parameters in GBM growth and progression; invasiveness,
proliferation index, and vessel intensity (Figure S1A):
(1) Invasiveness (Figures 2A and S3): the invasiveness of
each parental tumor was analyzed using MRI T2/FLAIR
images according to the response assessment in neuro-
oncology (RANO) criteria (Lutz et al., 2011), and a numer-
ical score for invasiveness was allocated comparingell Reports 3, 260–273, January 31, 2013 ª2013 The Authors 261
Table 1. Summary of the Clinical Data of GBM Patients and Experimental Results Derived from Primarily Cultured GBM Cells
Pt.
No. Exp. ID*
Clinical Data Experimental Data
Sex Age
Pathology
(Grade)
Ini.
KPS
Tx MRI Finding
Ki67 LI MVD
PFS
(Wk)
OS
(Wk) Status Subtype
Sphere
Form.b
In Vivo
Tumor
Form.c Invas.d
PCNA
LI MVD
Gene
Exp.
Rad.
Surg. CCRT
Tumor
Size
C/L
Inv. Invas.a
1 P07-428 M 29 GBM (IV) 90 Y Y 3.1 3 1.8 N 2 12.3 53 84 133 1 P ND N — — — Y
2 P07-436 F 56 GBM (IV) 40 Y Y 5.4 3 4.2 N 3 45.0 43 34 77 1 C Y Y Y 87.6 40 Y
3 P07-437 F 58 GBM (IV) 90 Y Y 6.0 3 5.0 N 1 32.7 19 30 71 1 C N Y Y 80.5 41 Y
P08-559 R-GBM (IV) 3 15.0 38 P Y Y 10.6 53 Y
4 P07-448 M 48 GBM (IV) 90 Y Y 5.8 3 4.0 N 2 12.2 8 13 13 1 UD Y Y Y 6.9 23 Y
5 P07-453 M 39 GBM (IV) 90 Y Y 6.8 3 6.7 N 2 5.0 52 122 170 1 P Y N — — — Y
6 P07-458 M 51 GBM (IV) 90 Y Y 4.9 3 3.2 N 1 73.7 11 56 149 1 M ND Y N 93.3 26 Y
P08-594 R-GBM (IV) 1 67.3 16 M ND Y 89.7 40 Y
7 P07-460 F 32 GBM (IV) 90 Y Y 5.9 3 4.9 N 1 74.0 17 49 110 1 UD ND Y Y 86.0 17 Y
P08-568 R-GBM (IV) 2 50.7 7 N Y Y 88.0 37 Y
8 P07-464 M 59 GBM (IV) 60 Y Y 6.3 3 4.9 N 1 7.5 16 120 184 1 P Y Y N 7.2 18 Y
9 P07-466 M 36 GBM (IV) 80 Y Y 5.7 3 5.0 Y 3 20.0 12 41 50 1 P ND Y Y 48.2 19 Y
10 P08-492 F 44 GBM (IV) 80 Y Y 4.0 3 3.0 N 1 6.8 12 214 214 0 M Y N — — — Y
11 P08-493 M 49 GBM (IV) 90 Y Y 4.0 3 2.0 Y 3 19.2 27 40 64 1 P Y Y Y 13.9 31 Y
12 P08-496 F 28 GBM (IV) 80 Y Y 5.5 3 3.5 Y 3 7.5 35 4 82 1 P N N — — — Y
13 P08-498 M 68 GBM (IV) 70 Y Y 5.5 3 5.0 N 1 38.0 42 64 64 1 P Y N — — — Y
14 P08-503 F 64 GBM (IV) 60 Y Y 4.6 3 5.2 N 2 1.4 39 71 99 1 C N N — — — Y
15 P08-531 F 71 GS (IV) 70 Y Y 4.5 3 3.0 Y 1 68.0 18 40 40 1 M ND Y Y 85.3 38 Y
16 P08-532 M 60 GBM (IV) 80 Y Y 2.5 3 2.0 N 2 1.0 16 4 4 1 C Y Y Y 68.0 37 Y
17 P08-538 F 37 GBM (IV) 80 Y Y 4.5 3 4.5 N 1 15.5 8 82 195 0 M Y Y N 82.0 20 Y
P09-773 R-GBM (IV) 2 28.0 9 M ND Y N 96.0 15 Y
18 P08-541 F 69 GBM (IV) 80 Y Y 4.5 3 3.0 N 1 13.8 38 39 157 1 C N Y Y 16.1 25 Y
19 P08-543 F 44 GBM (IV) 90 Y Y 4.0 3 3.5 N 3 1.0 39 44 184 0 M N N — — — Y
20 P08-558 F 45 GBM (IV) 90 Y Y 5.5 3 4.0 N 1 4.0 22 146 191 0 ND N N — — — N
21 P08-567 F 65 GBM (IV) 80 N N 3.2 3 2.3 N 3 37.1 19 39 - 2 M ND Y Y 71.4 23 Y
P09-732 R-GBM (IV) 3 2.0 8 M ND Y Y 6.5 ND Y
22 P08-570 F 60 GBM (IV) 80 Y Y 5.0 3 3.4 N 3 33.5 13 23 24 1 ND ND Y Y 94.0 22 N
23 P08-577 F 62 GBM (IV) 60 Y Y 5.7 3 3.6 Y 2 59.3 12 34 45 1 M Y Y Y 77.3 13 Y
P09-680 R-GBM (IV) 3 88.0 ND N N ND — — — Y
24 P08-578 M 68 GBM (IV) 90 N Y 4.0 3 3.0 N 2 37.1 25 67 73 1 P Y Y Y 11.3 12 Y
25 P08-580 F 46 GBM (IV) 70 Y Y 3.1 3 2.1 N 2 25.7 19 22 71 1 ND ND Y N ND ND N
26 P08-585 M 22 GBM (IV) 90 Y Y 3.2 3 2.7 N 2 20.4 47 54 123 1 N N N — — — Y
P09-663 R-GBM (IV) 2 48.7 9 M ND Y N 22.7 7 Y
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Table 1. Continued
Pt.
No. Exp. ID*
Clinical Data Experimental Data
Sex Age
Pathology
(Grade)
Ini.
KPS
Tx MRI Finding
Ki67 LI MVD
PFS
(Wk)
OS
(Wk) Status Subtype
Sphere
Form.b
In Vivo
Tumor
Form.c Invas.d
PCNA
LI MVD
Gene
Exp.
Rad.
Surg. CCRT
Tumor
Size
C/L
Inv. Invas.a
27 P08-586 M 40 GBM (IV) 80 Y N 5.2 3 4.2 N 1 23.3 10 11 28 1 P N Y N 74.7 17 Y
P09-647 R-GBM (IV) 1 82.0 1 P ND Y N 47.3 6 Y
28 P08-592 M 44 GBM (IV) 90 Y Y 4.5 3 2.5 N 2 75.3 8 29 64 1 M Y Y Y 83.3 13 Y
P09-660 R-GBM (IV) 3 7.2 56 M Y Y Y 3.4 31 Y
29 P08-608 F 43 GBM (IV) 80 Y N 2.6 3 2.7 N 1 62.0 13 88 144 1 P N Y Y 86.7 35 Y
30 P08-609 M 48 GBM (IV) 90 Y Y 4.5 3 3.0 N 1 53.6 41 45 82 1 M Y Y Y 86.7 35 Y
31 P09-626 M 67 GBM (IV) 90 Y Y 7.5 3 5.0 N 1 5.2 35 79 88 1 C Y Y N 19.1 39 Y
32 P09-630 F 44 GBM (IV) 60 Y N 4.4 3 2.8 N 3 14.6 12 8 53 1 P N Y Y 10.3 18 Y
33 P09-631 F 53 GBM (IV) 90 Y Y 5.5 3 3.5 N 1 1.0 16 14 82 1 N N N — — — Y
34 P09-633 F 36 GBM (IV) 80 Y N 4.0 3 3.0 N 1 6.7 17 119 270 0 N N Y N 22.3 17 Y
35 P09-671 F 47 GBM (IV) 90 Y Y 6.6 3 4.1 N 3 73.3 5 29 48 1 P Y Y Y 88.0 18 Y
P09-740 R-GBM (IV) 3 ND ND N Y N — — — Y
36 P09-672 F 76 GBM (IV) 90 Y Y 4.0 3 3.0 N 3 54.0 9 12 12 1 M N N — — — Y
37 P09-676 M 51 R-GBM (IV) 70 Y N 2.3 3 1.8 N 1 34.3 13 - - 0 ND ND Y N 73.3 8 N
P09-723 R-GBM (IV) 2 26.7 52 M ND Y N 62.1 ND Y
38 P09-690 M 57 GBM (IV) 90 Y Y 5.5 3 5.0 N 3 16.4 17 36 61 1 P Y Y Y 72.6 24 Y
39 P09-696 M 70 GBM (IV) 50 Y Y 4.8 3 3.1 N 3 3.9 22 54 54 1 C N Y Y 25.6 28 Y
40 P09-705 M 67 GBM (IV) 70 Y Y 2.8 3 2.2 N 3 50.0 9 34 51 1 ND Y N — — — N
41 P09-727 M 61 GBM (IV) 90 Y Y 5.0 3 3.4 N 2 40.0 15 38 80 1 M N Y N 82.3 20 Y
42 P09-745 M 58 GBM (IV) 70 Y Y 3.9 3 3.8 N 2 15.2 15 17 102 1 C Y Y Y 63.3 30 Y
43 P09-748 M 51 GBM (IV) 70 Y Y 6.5 3 4.5 Y 3 30.0 40 40 40 0 P Y Y Y 45.3 34 Y
44 P09-751 F 46 GBM (IV) 60 N Y 4.4 3 3.4 N 3 17.1 21 54 87 1 M Y Y Y 54.0 31 Y
45 P09-763 M 66 GBM (IV) 70 Y Y 3.1 3 2.6 N 2 21.0 16 49 59 1 ND ND Y Y 54.2 ND N
46 P09-776 M 58 GBM (IV) 70 Y Y 5.3 3 4.8 N 3 20.2 24 50 63 1 ND ND N — — — N
47 P09-780 M 74 GBM (IV) 40 Y Y 6.6 3 3.6 N 2 30.0 21 24 65 1 P Y Y Y 67.2 32 Y
I10-025 R-GBM (IV) 3 32.1 17 M ND Y N 41.2 24 Y
48 P09-788 M 62 GBM (IV) 60 Y Y 5.8 3 5.4 N 3 16.5 9 53 56 1 ND ND N — — — N
49 I10-011 F 30 GBM (IV) 60 N Y 4.7 3 2.8
3.6 3 1.7
N 2 41.8 29 69 89 0 C Y Y N 75.5 36 Y
50 I10-016 M 67 GBM (IV) 60 Y Y 6.7 3 6.1 N 2 79.3 10 37 60 1 C Y Y Y 81.2 16 Y
51 I10-022 M 63 GBM (IV) 40 N Y 6.0 3 3.2 N 3 30.0 20 - - 2 P ND Y Y 83.5 43 Y
52 I10-023 M 31 GBM (IV) 90 Y Y 5.0 3 3.7 N 1 50.0 11 64 89 0 C ND Y N 83.2 19 Y
53 I10-029 F 50 GBM (IV) 80 Y Y 3.5 3 2.4 N 2 16.7 14 38 63 1 ND Y N — — — N
54 I10-042 M 49 GBM (IV) 90 N Y 4.5 3 3.2 N 3 11.8 21 37 79 1 ND Y N — — — N
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Interestingly, comparison of the patient MRI and invasive-
ness of xenograft tumors revealed that invasiveness of
parental and corresponding xenograft tumors were signif-
icantly correlated (n = 42, c2 test, p = 0.029).
(2) Proliferation index (Figure 2B): proliferation index of xeno-
graft tumors was positively correlated with that of their
parental tumors (n = 53, Pearson correlation, p < 0.001).
(3) Microvessel density (Figure 2C): CD31-positive microves-
sel density of xenograft tumors showed significant posi-
tive correlation with that of their parental tumors (n = 53,
Pearson correlation, p < 0.001).Genomic Similarity
To further examine the similarities between parental tumors and
the corresponding orthotopic xenograft tumors, we performed
genomic analysis. First, we performed short tandem repeat
(STR) genotyping to ensure that each GBM xenograft was
derived from the specific patient (Figure 3A). Analysis of array-
comparative genomic hybridization (aCGH) (Figure 3B) and
genetic mutation (Figure 3C) indicated that all examined
genomic alterations found in the parental GBMs including copy
number variations and genetic mutations were precisely repli-
cated in the corresponding xenograft tumors.
A recent large genomic study categorized GBMs into four
subgroups (proneural, neural, classical, and mesenchymal)
(Cancer Genome Atlas Research Network, 2008; Phillips et al.,
2006; Verhaak et al., 2010) based on their distinct gene expres-
sion signatures. In order to determine whether our library covers
full spectrum of these subtypes and test whether gene expres-
sion signatures of a parental tumor are maintained in the ortho-
topic xenograft tumor, we performed global gene expression
profiling analysis. We analyzed 58 GBM patients’ surgical spec-
imens, for whichmicroarray gene expression data were available
(Table 1). We also performed tissue microarray (TMA) analysis
that encompasses the parental GBMs and corresponding ortho-
topic xenograft tumors. For the subtype determination, we adop-
ted the nearest template prediction algorithm (Hoshida, 2010) for
single-sample-based determination of subtypes. The analysis
identified 18 proneural, 6 neural, 13 classical, and 19 mesen-
chymal GBMs in the data set (two undetermined; Table 1; Fig-
ure 3D). On TMA sections, we performed a series of immunohis-
tochemical analysis against distinct GBM subtype markers;
DLL3, SOX2, and Olig2 (proneural), MBP (neural), PDGFA and
EGFR (proneural), CHI3L1, MAP2, and TOP2A (mesenchymal)
(Phillips et al., 2006; Verhaak et al., 2010). Preferential expres-
sion of each subtype marker proteins was detected both in the
parental GBM specimens and the corresponding xenograft
tumors (Figure 3E).Functional Relevance
We examined whether the patient-specific response to standard
therapies could be replicated in the orthotopic xenograft tumor
models.
Radiation Therapy
We arbitrarily chose five patients who had received radiation
treatment in the clinic after resection of primary tumors (four
Figure 1. Primary Cultures and Orthotopic
Xenograft Animal Models Derived from
GBM Surgical Samples
(A) Acutely dissociated GBM cells were primarily
cultured in the NBE condition or stereotactically
injected into the brains of immune-compromised
NOG mice. Immunohistochemistry against PCNA
was illustrated for orthotopic xenograft tumors.
Arrowheads indicate the border of a PCNA-posi-
tive xenograft tumor.
(B) Correlation between in vitro sphere formation
capacity and in vivo tumorigenicity of acutely
dissociated GBM cells was analyzed by the
Fisher’s exact test (p = 0.09).
(C) The PFS and OS of the GBMs with in vivo
tumorigenic potential (n = 40) were compared with
those without the potential (n = 16) by using the
Kaplan-Meier plots and log rank test.
See also Figure S2.from our library, one from our recently published study [‘‘827,’’
PFS = 128 weeks] [Son et al., 2009]), and subjected their corre-
sponding xenograft tumors to in vivo whole brain irradiation
(2Gy daily for 5 days). Survival of the mice bearing PC-NS07-
448, PC-NS07-464, PC-NS08-578, PC-NS09-780, and 827
tumors was differentially increased by the radiation therapy
(21.9% ± 7.1%, 49.8% ± 14.1%, 45.9% ± 8.6%, 23.3% ±
19.5%, and 45.0% ± 5.9%, respectively, Figures 4A and S4A).
The increment of survival was positively correlated with the
PFS of the parental tumors (Figure 4A). Radiation-mediated
survival benefits of the mice bearing the GBMs (PC-NS07-448
and PC-NS09-780) whose parental tumors have relatively
short-PFS, are significantly less than those of the other GBMs
with longer PFS (Figure 4A), suggesting that the radiation-
response of the parental GBM can be predicted by the xeno-
graft tumor model.
To further elucidate clinical implications of the differential
response to the radiation therapy, we derived Radio-Response
(RR) signature by comparing gene expression alteration of the
radioresistant PC-NS07-448 (‘‘448’’) and radiosensitive PC-
NS07-464 (‘‘464’’) xenograft tumors after the radiation therapy
(Figure S4B; Tables S1 and S2; Extended Experimental Proce-
dures). Based on the gene expression, high-grade gliomas in
the REMBRANDT data set (n = 463) (Madhavan et al., 2009)
were clustered into 448-like (n = 267) and 464-like (n = 196) group
(Figure S4B). When we restrict the samples to 219 GBMs (grade
IV), 174 and 45 GBMs were clustered into 448-like and 464-like
group, respectively. Both the 448-like high-grade gliomas and
GBMs showed significantly worse clinical outcome than theCell Reports 3, 260–273464-like groups (Figure S4B), confirming
the clinical relevance of the RR signature.
Chemotherapy
GBMpatients differentially respond to the
TMZ-based chemotherapy depending on
the methylation status of theMGMT gene
promoter (Hegi et al., 2005; Stupp et al.,
2005). We tested whether the differential
response could be reproduced in xeno-graft tumors. In agreement with the clinical observation, TMZ
chemotherapy prolonged the OS of mice with MGMT-methyl-
ated PC-NS07-464 tumors (148.5% ± 45.4%) significantly
more than that of mice harboring MGMT-unmethylated PC-
NS09-559 tumors (55.7% ± 38.6%, p < 0.001, Figure 4B).
Targeted Therapy
The hypervascular nature of GBMs has suggested that antian-
giogenic treatment, such as the VEGF-neutralizing antibody,
bevacizumab, may have beneficial activity. Although it showed
treatment effects on the animal model using a conventional
GBM cell line, U-87MG (de Groot et al., 2010), it failed to
elongate OS of GBM patients compared to that of standard
treatment controls (Lai et al., 2011). When we tested anti-
tumor activity of bevacizumab, survival of mice with PC-NS07-
448, PC-NS07-464, PC-NS08-559, or PC-NS09-748 xenograft
tumors was not altered by bevacizumab treatment (Figure 4C).
Although OS was not altered, the treatment made xenograft
tumors more invasive (Figure 4C). These morphological changes
were also observed in human GBMs with bevacizumab treat-
ment (Lai et al., 2011), which suggest that xenograft tumors
derived from GBM surgical samples would predict the results
of clinical trial.
Genetic Signature of In Vivo Tumorigenic Potential
Our data indicated that in vivo tumorigenic potential of primarily
cultured GBM cells is associated with clinical aggressiveness of
the corresponding patients, although it was not statistically
significant (Figure 1C). We reasoned that the shortage of statis-
tical significance was due to the small sample size, and that the, January 31, 2013 ª2013 The Authors 265
Figure 2. Representation of Morphologic
and Pathologic Characteristics of Parental
GBMs by the Corresponding Orthotopic
Xenograft Tumors
(A–C) The invasiveness (A), proliferation index (B),
and microvessel density (C) of the parental and
corresponding orthotopic xenograft tumors were
analyzed and compared. (A) The invasive parental
and xenograft tumor was defined by comparisons
of the distances of infiltration with the diameters
of main mass in MRI and pathologic sections,
respectively. (B) Proliferation index was analyzed
by immunohistochemistry against Ki-67 (parental
GBMs) or PCNA (xenograft GBMs) and then
calculated as number of positive cells from 100
cells selected randomly. Each index was analyzed
three times and the average was utilized for the
statistical analysis. (C) Microvessel density was
analyzed by immunohistochemistry against CD31.
Three microscopic fields were randomly selected
at 2003 magnification and the numbers of CD31-
posive microvessels were calculated. Averages
for the three were utilized for the statistical
analysis.
See also Figure S3.gene expression difference between the tumorigenic and nontu-
morigenic groups may nonetheless capture information that is
useful for predicting patient survival and understanding biolog-
ical underpinnings of differential aggressiveness. We therefore
defined the ‘‘tumorigenesis’’ signature composed of 709 differ-
entially expressed genes (change more than 1.5-fold; Figure 5A;
Table S3) between tumorigenic (n = 36; Table 1; Figures S1A and
S1C) and nontumorigenic GBMs (n = 10). To validate this signa-
ture, we applied this to two independent GBM gene expression
profiling data sets, the Cancer Genome Atlas (TCGA) (Cancer
Genome Atlas Research Network, 2008; Verhaak et al., 2010)
and REMBRANDT (Madhavan et al., 2009). Nearest template
prediction algorithm allowed for prediction of each GBM patient
into two groups, each either positively or negatively associated
with the tumorigenesis signature. When patient survival was
compared between the two groups, the positive-group showed
significantly worse survival than the negative-group with the
REMBRANDT data set (p < 0.0001, log rank test; Figure 5B).
Permutation analysis indicated that such or more severe separa-
tion in survival is unlikely observed by chance (p = 0.004), poten-
tiating the validity of the signature (Figure S5A). The statistically
significant trend was also observed with the TCGA data set
(p = 0.019, log rank test, data not shown).
To investigate the biological underpinnings of the differential
tumorigenic potential and the clinical aggressiveness, we turned
to pathway analysis using the gene set enrichment analysis
(GSEA) (Clark and Ma’ayan, 2011; Subramanian et al., 2005).266 Cell Reports 3, 260–273, January 31, 2013 ª2013 The AuthorsThe analysis revealed that pathways
related to cell cycle, telomere mainte-
nance, transcription, Notch signaling, or
Wnt signaling were upregulated in the
GBMs with in vivo tumorigenic potential,
whereas pathways related to neuronalor immune functions were downregulated (Table S4). If these
pathways influence clinical aggressiveness in GBMs, the activity
of the pathways would predict patient survival. We devised
a method to calculate pathway activity for each patient based
on the gene expression profile; the pathway activity is defined
between 1 and 1, with the score bigger than 0 and smaller
than 0 indicating up- and downregulation, respectively. When
the pathway activity for the PITX2 pathway (PITX2 is a transcrip-
tion factor, acting downstream of WNT) was calculated for each
patient of the REMBRANDT data set, we detected that the ones
upregulating the pathway corresponds to the ones with poorer
survival (p = 0.002, log rank test; Figure 5C). Alternatively, by
Cox proportional hazard regression, high pathway activity was
significantly correlated with poor patient survival (p = 0.007,
one-sided Wald test; Figure 5D). When this analysis was
expanded to five most highly upregulated and downregulated
pathways in the BIOCARTA (Figure 5D), KEGG (Figure S5B),
and REACTOME (Figure S5C) databases, we observed the
significant trend that the pathways upregulated or downregu-
lated in the GBMs with in vivo tumorigenic potential are corre-
lated with poor or favorable patient survival, respectively (p <
0.05 for all three databases, KS test).
As the GBMs that made invasive tumors (n = 29) in the mouse
brain showed significantly worse clinical outcomes in our data
set, when compared to those that made noninvasive (demar-
cated) tumors (n = 13) or did not made tumors (n = 16) (Fig-
ure S2B), we sought for the opportunity to further stratify
Figure 3. Molecular Characteristics of Parental and Orthotopic Xenograft Tumors
(A–E) Short tandem repeat (A), genomic copy number variation (B), genetic mutation of TP53 and IDH1 (C), and gene expression pattern (D and E) of parental
GBMs were compared with those of the corresponding orthotopic xenograft tumors. (B) Genomic copy number variation was analyzed by aCGH (left), and the
genomic copy number variations of the genes that were reported to be altered frequently in GBMs were summarized (right; red, amplified; green, deleted).
(C) Specific mutations were indicated by red. wt, wild-type. (D) Subtypes of the 58 GBM samples were determined by the Nearest Template Prediction method.
(E) Expression of gene products was compared immunohistochemically between parental GBMs and orthotopic xenograft tumors using TMA containing 11
parental GBMs and corresponding orthotopic xenograft tumors. Nuclei are presented in blue.
See also Table S6.
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Figure 4. Functional Representation of Treatment Responsiveness of Parental Tumors by the Corresponding Orthotopic Xenograft Tumors
(A) Xenograft tumors derived from PC-NS07-448, PC-NS07-464, PC-NS08-578, PC-NS09-780, or 827 tumor (n = 8, 15, 9, 9, and 4 for the control [C] group, n = 9,
9, 10, 9, and 4 for the radiation [RT] group, respectively) were treated with whole brain radiation therapy (2Gy daily for 5 days since 50% median survival time
passed). OS was calculated and then increase in the survival length by the whole brain irradiation was compared (left). *p < 0.05. Increase in the survival length of
xenograft tumors was correlated with PFS of parental tumors (right). Error bar represents SD.
(B) Methylation status of theMGMT promoter was analyzed by methylation specific PCR (left, M, methylation specific primers or methylated control gDNA; UM,
methylation specific primers or unmethylated control gDNA). Xenograft tumors derived from PC-NS07-464 or PC-NS09-559 (n = 9, 10 for the control [C] group,
n = 7, 9 for the TMZ group, respectively) were treated with TMZ (65 mg/kg, oral administration, daily since 50%median survival time passed). OS was calculated
and then increase in the survival length by the TMZ chemotherapy was compared. *p < 0.05. Error bar represents SD.
(legend continued on next page)
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tumorigenic GBMs based on their differential invasiveness. To
validate whether the group with the invasion property represents
more aggressive GBMs, we compared gene expression of the
‘‘invasive’’ (n = 29) and ‘‘demarcated’’ (n = 13) groups. We iden-
tified 777 differentially expressed genes (change more than 1.5-
fold; Figure S6A; Table S5; Extended Experimental Procedures),
which was defined as the ‘‘invasion’’ signature. To validate this
signature, we again used the REMBRANDT data sets, as did
for the tumorigenesis signature. When patient survival time
was compared between the two groups, the invasive group
showed significantly worse survival than the demarcated group
(p = 0.027, log rank test; Figure S6B), suggesting possible clinical
relevance of the invasion signature.DISCUSSION
There have been many efforts and interests on the xenograft
tumors derived from the patient cancer cells as human cancer
surrogates for therapeutic purposes (DeRose et al., 2011; Fu
et al., 1992; Giannini et al., 2005; Groves et al., 2002; Horten
et al., 1981; Karam et al., 2011; Marangoni et al., 2007; Rubio-Vi-
queira etal., 2006;Wangetal., 2009;Xieet al., 2008;Yi et al., 2011;
Zhuo et al., 2010). However, the concept, ‘‘preclinical animal
models derived fromprimary cancer cells would recapitulate their
parental tumors faithfully,’’ remains unsolved because themolec-
ular andbiological validityofpreclinicalmodelshasnotbeen rigor-
ously tested by a large-scale library. The results presented in this
manuscript may provide an in-depth validation to support the
above concept.
Tumor microenvironment can critically affect the biological
behavior of xenograft tumors (Charles et al., 2011; Langley and
Fidler, 2011; Lathia et al., 2011). Infiltrative pattern of GBM
growth, a critical pathological characteristic of human GBM,
was frequently lost when the tumor graft was established in
mice flanks (Antunes et al., 2000). Therefore, orthotopic implan-
tation of our study would overcome potential limitations associ-
ated with heterotypic transplantation in the previous studies
(DeRose et al., 2011; Fu et al., 1992; Giannini et al., 2005;
Groves et al., 2002; Horten et al., 1981; Karam et al., 2011; Mar-
angoni et al., 2007; Rubio-Viqueira et al., 2006;Wang et al., 2009;
Yi et al., 2011; Zhuo et al., 2010) and increase the validity of the
preclinical platform. Our xenograft model still has caveats, as the
murine brain microenvironment has molecular and functional
differences in comparison to the human brainmicroenvironment.
Future development of mouse models such as reducing the
incompatibility of cytokines and integrins between species
would help better mimic the natural tumor environment of
human GBM.
Differential clinical response of GBMs to TMZ chemotherapy
according to the MGMT expression (Hegi et al., 2005; Stupp
et al., 2005) and accumulating evidence indicating GBM(C) Xenograft tumors derived fromPC-NS07-448, PC-NS07-464, PC-NS09-559, o
Bevacizumab group, respectively) were treated with Bevacizumab (10 mg/kg, intr
Morphologic alteration of the xenograft tumors by Bevacizumab treatment was
NS07-464).
See also Tables S1, S2, and Figure S4.
Cheterogeneity in the genomic make-ups and phenotypic
properties (Martens et al., 2008; Sausville and Burger, 2006;
Taillandier et al., 2003) potentiate personalized approach for
the maximal therapeutic benefit. This study could present
conceptual and experimental background for the personalized
translational research with functional genomics. Our data
support the following notion: (1) orthotopic xenograft animal
models could predict differential results of clinical treatment
of the parental tumors, (2) the translational platforms we
built represent intratumoral heterogeneity of human GBMs to
therapeutic modalities, and (3) analysis of genetic differences
between responding and nonresponding xenograft tumors
could draw clinically meaningful biomarkers discriminating
patient populations with different prognosis. Based on these
capacities, the personalized preclinical/translational research
would lead to more successful rationale-driven clinical trials
with target subpopulation for newly developed therapeutic
agents. Although this article was focused to GBMs, these
translational implications would be adoptable to other cancer
types.
Significant association between the capacity of forming a
xenograft tumor and clinical aggressiveness of the parental
GBMs has several important preclinical and clinical implica-
tions. First, bidirectional approaches between translational
library and cancer patient population. A preclinical platform
could represent the specific responses of cancer patients to
a newly developed anticancer agent. Conversely, novel thera-
peutic and/or diagnostic targets for cancer patients could be
identified by analysis of preclinical models. In this study, we
successfully identified the molecular candidates to discriminate
GBM patients with worse clinical prognosis using in vivo tumor-
igenicity of primary GBM cells or invasive properties of resulting
xenograft tumors, and validated them using independent GBM
data sets. Second, translational models representing aggressive
pheno- and genotypes of the GBM would provide ideal preclin-
ical models for the rationale-driven clinical trials overcoming the
treatment resistance of the GBM, because aggressive pheno-
and genotypes of the GBM would be manifested by the treat-
ment resistance.
In summary, we demonstrated that orthotopic GBM xenograft
models derived from the acutely dissociated GBM cells are pre-
clinically and clinically relevant models that can functionally
represent the biology of human GBMs in situ.EXPERIMENTAL PROCEDURES
GBM Patients and Primary Cell Culture
Following informed consent, surgical specimens and clinical records were
obtained from 59 GBM patients who had brain tumor removal surgery at
the Samsung Medical Center (Seoul, Korea) in accordance with the appro-
priate Institutional Review Boards (Table 1). Tumors were classified as GBM
based on WHO criteria by examination of pathologists (Louis et al., 2007).r PC-NS09-748 (n = 8, 8, 7, and 7 for the control group, n = 9, 11, 7, and 6 for the
aperitoneal injection, twice per week since 50%median survival time passed).
analyzed by H&E and immunohistochemistry against human nuclei (low, PC-
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Figure 5. The Tumorigenesis Signature, Tumorigenesis-Associated Pathways, and Their Association with Clinical Outcome in an Inde-
pendent Data Set
(A) Expression of 709 genes that are differentially expressed (cutoff, changemore than 1.5-fold) between 10 nontumorigenic and 36 tumorigenic GBMs, plotted as
a heat map after row-normalization. Red and blue indicate high and low expression, respectively. The 20 genes most highly differentially expressed with each
group are listed on the sides.
(B) A Kaplan-Meier plot comparing cumulative OS of two groups of patients in the REMBRANDT data set, with each group either positively or negatively
associated with the tumorigenesis signature.
(C) A Kaplan-Meier plot comparing the OS of two groups of patients in the REMBRADNT data set, with each group either up- or downregulating the PITX2
pathway (p = 0.002, log rank test).
(D) A forest plot displaying hazard ratios (in a natural log scale) and their 95% confidence intervals, with each hazard ratio representing the correlation between the
calculated activity of a given pathway and the OS of patients in the REMBRANDT data set. The top five (red) and bottom five (blue) entries correspond to the
pathways in BIOCARTA that were found most up- and downregulated, respectively, in the group positively associated with the tumorigenesis signature.
See also Table S3, S4, and S5, and Figures S5 and S6.Parts of the surgical samples were enzymatically dissociated into single cells,
following the procedures previously reported (Joo et al., 2008). Dissociated
GBM cells were cultured in neurobasal media with N2 and B27 supplements
(0.53 each; Invitrogen) and human recombinant bFGF and EGF (25 ng/ml270 Cell Reports 3, 260–273, January 31, 2013 ª2013 The Authorseach; R&D Systems) (NBE condition). Alternatively, acutely dissociated
GBM cells in the NBE condition were plated on the flasks, coated with Laminin
(Sigma) overnight at 10 mg/ml prior to use, for the adherent culture (Pollard
et al., 2009).
Orthotopic Xenograft Animal Model
Animal experiments were approved by the Institutional Review Boards of the
Samsung Medical Center and conducted in accordance with the "National
Institutes of Health Guide for the Care and Use of Laboratory Animals" (NIH
publication 80-23). Acutely dissociated GBM cells were stereotactically
(2 mm left and 1mm anterior to the bregma, 2mmdeep from the dura) injected
into the brains of NOG mice (Ito et al., 2002) within 12 hr after surgery (2.5 3
104–1.0 3 105 cells in 10 ml HBSS for each mice, n = 4–9 for each sample).
Mice with the reduction of the total body weight (>20%) were sacrificed, and
brains were processed for paraffin or frozen section.
Whole-Brain In Vivo Irradiation, TMZ Chemotherapy, and
Bevacizumab-Targeted Therapy
Orthotopic xenograft tumors were made as described previously, using
primarily cultured GBM cells that had short term in vitro culture in the NBE
condition (in vitro passage <6, 2.0 3 105 cells for each animal). Treatments
were started at the half of the median survival length of the orthotopic xeno-
graft animal models. The reduction of the total body weight (>20%) was
regarded as mortality. Whole brain 2Gy X-irradiations were applied daily
for 5 days (total 10Gy) using a blood irradiator (IBL-437C, CIS-US).
Mouse bodies were shielded with a custom-made lead shield device. TMZ
(65 mg/kg) was orally administrated daily. Methylation status of the MGMT
gene promoter was determined as previously reported (Yang et al., 2009).
Bevacizumab (10 mg/kg, twice per week) was injected into the intraperitoneal
space.
TMA and Immunohistochemistry
A TMA containing 11 parental GBMs and corresponding orthotopic xenograft
tumors (PC-NS07-464, PC-NS08-493, PC-NS08-532, PC-NS08-559, PC-
NS08-608, PC-NS09-626, PC-NS09-630, PC-NS09-633, PC-NS09-660, PC-
NS09-690, and PC-NS09-696) was produced as previously described (Kong
et al., 2009). Immunohistochemistry was performed as described previously
(Kong et al., 2009). Primary antibodies included Ki-67, PCNA (DAKO), DLL3
(Santa Cruz), SOX2, Olig2, MAP2 (Abcam), MBP, PDGFA, EGFR (Santa
Cruz), CHI3L1, TOP2A (LifeSpan Bioscience), and CD31 (DAKO for xenograft
tumors and BD PharMingen for parental tumors).
STR Genotyping, aCGH, and Genetic Mutation of TP53 and IDH1
Genomic DNA was isolated from tumor sample using QIAamp DNA mini kit
(QIAGEN). For STR genotyping, target DNA was amplified by multiplex PCR
for 16 loci using the AmpFlSTR Identifier PCR Amplification Kit (Applied Bio-
systems). PCR products mixed with internal size standard (GS-500 LIZ,
Applied Biosystems) were electrophoresed in an ABI 3130xL Genetic Analyzer
(Applied Biosystems) and analyzed with GeneMapper 4.0 software using the
supplied allelic ladders (Applied Biosystems). aCGH was performed using
the Agilent Human Whole Genome CGH 244K microarray. For genetic muta-
tion of TP53 and IDH1, PCR reactions (40 cycles, at 95C for 30 s, 58C for
30 s, and 72C for 30 s) were carried out in 20 ml volume that contained
100 ng of gDNA, 200 nM each primer (Table S6), and Maxime PCR premix
(iNtRON). PCR products were purified by QIAquick PCR purification kit
(QIAGEN) and bidirectional sequencing was performed using the BigDye
Terminator v1.1 kit (Applied Biosystems) on an ABI 3130xl genetic analyzer
(Applied Biosystems).
Gene Expression Profiling
Gene expression profiling was conducted using Affymetrix Human Gene
1.0 ST arrays. The resulting CEL files were normalized using Robust
Multichip Averaging procedure. PM-MM difference model was used to
obtain the expression values. The probe IDs were resolved into gene names
by using GSEA-P program (downloadable from Broad Institute website). For
the REMBRANDT data set (Madhavan et al., 2009), CEL files for high-grade
glioma samples were downloaded from the website (https://caintegrator.nci.
nih.gov/rembrandt/), along with a matching clinical information file. The CEL
files were processed as were the in-house produced CEL files, except
a matching array annotation file (for Affymetrix U133 Plus 2.0 array) was
used. For the TCGA data set (Cancer Genome Atlas Research Network,
2008; Verhaak et al., 2010), gene expression data files for 556 GBM samplesCoriginally produced using Affymetrix U133A 2.0 arrays were downloaded
from the official website, along with a matching clinical information file.
The gene expression files were provided in an already processed form
(Level III).
GBM Subtype Prediction
Among the 840 marker genes originally used to classify GBM subtypes (Ver-
haak et al., 2010), 787 were represented in the microarray platform we used.
The 787 genes were annotated with the numeric code representing the unique
subtype that each gene represents (1, 2, 3, and 4 for proneural, neural, clas-
sical, and mesenchymal markers, respectively, and 5 for the rest). The marker
gene information file and the file containing the gene expression data for 58
GBM samples were loaded into Nearest Template Prediction module in
GenePattern (available through Broad Institute). All samples were classified
into one of the five categories with statistical significance (with Bonferroni
p value below 0.05, bootstrap test with 1,000 resampling).
Gene Signature Analysis
The 46 in-house-profiled GBM samples were subject to the tumorigenesis
signature analysis (Figures S1A and S1C). Genes differentially expressed
(changes more than 1.5-fold) between the tumorigenic and nontumorigenic
group (n = 36 and 10, respectively) were identified. The tumorigenesis signa-
ture was composed of the differentially expressed genes, with each labeled
with the associated subgroup and a value for log2-fold change. The signature
was loaded into the Nearest Template Prediction module in GenePattern. Also
loaded into the module was either the REMBRANDT or the TCGA data set in
GCT format. Themodule produced an output file with classification of samples
in each data set. Survival analysis (Kaplan-Meier plot and log rank test) was
performed using R Survival package. For permutation analysis, we randomly
regrouped the GBM patients into tumorigenesis and nontumorigenesis
subgroups, maintaining the size of the original subgroups. A ‘‘control’’ signa-
ture was derived and applied to the REMBRANDT data set for prognostic
prediction, as was done with the original unshuffled data set. The fraction of
the resulting 500 p values (from log rank test) smaller than the original p value
of the unshuffled data set (p = 0.000046) was defined as the p value of the
permutation test.
Pathway Analysis
Identification of the In Vivo Tumorigenesis-Associated Pathways
The 46 in-house-profiled GBM samples were subject to pathway analysis by
using the GSEA-P program. The analysis utilized gene sets in MSigDB v3.0:
specifically gene sets that are derived from three major manually-curated
pathway databases: KEGG, REACTOME, and BIOCARTA. Genes were
ranked and weighted by the degree of differential expression, quantified by
Z scores (adjusted from T scores of t test). For the permutation_type param-
eter: an alternative option (gene_set) was used instead of the default option
(phenotype). This alternative setting tends to give more generous p values;
indeed, many of the in vivo tumorigenesis-associated pathways listed in
Table S4 fell below a traditional significance cutoff (FDR < 0.25) under the
default setting. We nonetheless used the alternative setting, because (1)
the default setting is likely to give excessively conservative significance
assessments when the number of samples is small, and (2) most of the path-
ways that pass the significance cutoff only at the alternative setting showed
the expected trend of correlation with patient survival in the REMBRANDT
data set.
Quantification of Pathway Activity from a Gene Expression Data Set
For the REMBRANDTdata set, expression valueswere ‘‘gene-normalized’’: for
each gene, the log expression value for each sample was offset by the average
log expression value of the gene across all the samples. To calculate the
activity of a given pathway in a given sample, the relative expression values
of the pathway genes were compared to the relative expression values of all
genes. KS score (Python Stats package) was used for the comparison; the
score is defined between 1 and 1, with the value bigger and smaller than
0 indicates the pathway genes are up- and downregulated, respectively,
compared to all genes in the given sample. R Survival package was used to
(1) plot patient survival of samples up- and downregulating a given pathway,
(2) assess statistical significance of the difference in survival between theell Reports 3, 260–273, January 31, 2013 ª2013 The Authors 271
two groups, and (3) calculate hazard ratio of the KS score (pathway activity) for
OS (by the Cox proportional hazard regression).
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